Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma

Pfaar, Oliver; Bachert, Claus; Kuna, Piotr; Panzner, Petr; Dzupinova, M; Klimek, Ludger; Nimwegen, Maroesja J. van; Boot, J. D.; Yu, Dong; Opstelten, Dirk Jan E.; Kam, Pieter-Jan de

doi:10.1016/j.jaci.2018.11.018

Cited by 34 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as defined by the EAACI as standard primary endpoint for future (pivotal) trials in AIT 342 has been recently used recently in an increasing number of key trials in AIT. [343][344][345] However, further formal validation and amendments especially for the pediatric population are needed. 334,346 As another example, a further Task Force initiative aimed to provide clear clinically and aerobiologically justified definitions of pollen counts for onset, peak and duration of pollen seasons 347 and they have been confirmed to be robust 348 and clinically relevant as reflecting patients' symptom load in different countries in Europe in recent reports.…”

Section: B I Omark Er S Of the Epithelial Barriermentioning

confidence: 99%

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Breiteneder

Peng

Agache

et al. 2020

Allergy

Self Cite

175

150

View full text Add to dashboard Cite

show abstract

Section: B I Omark Er S Of the Epithelial Barriermentioning

confidence: 99%

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Breiteneder

Peng

Agache

et al. 2020

Allergy

Self Cite

175

150

View full text Add to dashboard Cite

show abstract

“…AIT was previously shown to prevent the development of new sensitizations in HDM monosensitized children (161). The European Academy of Allergy and Clinical Immunology (EAACI) guidelines on AIT for allergic asthma and the new Global Initiative for Asthma (GINA) guidelines now include HDM SCIT (162). It is also worth noting that recent SLIT-based AIT trials in house dust mite (HDM) allergic asthma have shown some efficacy.…”

Section: Therapeutic Approaches To Hdm-induced Allergymentioning

confidence: 99%

Insights Into Mucosal Innate Immune Responses in House Dust Mite-Mediated Allergic Asthma

et al. 2020

View full text Add to dashboard Cite

The prevalence of asthma has been rising steadily for several decades, and continues to be a major public health and global economic burden due to both direct and indirect costs. Asthma is defined as chronic heterogeneous inflammatory diseases characterized by airway obstruction, mucus production and bronchospasm. Different endotypes of asthma are being recognized based on the distinct pathophysiology, genetic predisposition, age, prognosis, and response to remedies. Mucosal innate response to environmental triggers such as pollen, cigarette smoke, fragrances, viral infection, and house dust mite (HDM) are now recognized to play an important role in allergic asthma. HDM are the most pervasive allergens that co-habitat with us, as they are ubiquitous in-house dusts, mattress and bedsheets, and feed on a diet of exfoliated human skin flakes. Dermatophagoides pteronyssinus, is one among several HDM identified up to date. During the last decade, extensive studies have been fundamental in elucidating the interactions between HDM allergens, the host immune systems and airways. Moreover, the paradigm in the field of HDM-mediated allergy has been shifted away from being solely a Th2-geared to a complex response orchestrated via extensive crosstalk between the epithelium, professional antigen presenting cells (APCs) and components of the adaptive immunity. In fact, HDM have several lessons to teach us about their allergenicity, the complex interactions that stimulate innate immunity in initiating and perpetuating the lung inflammation. Herein, we review main allergens of Dermatophagoides pteronyssinus and their interactions with immunological sentinels that promote allergic sensitization and activation of innate immunity, which is critical for the development of the Th2 biased adaptive immunity to HDM allergens and development of allergic asthma.

show abstract

“…Numerous clinical trials have demonstrated the benefit of allergen immunotherapy via both subcutaneous and sublingual tablet routes of administration for birch‐related allergic rhinoconjunctivitis . Novel epicutaneous patch delivery systems for birch AIT are also under development .…”

Section: Introductionmentioning

confidence: 99%

Birch pollen allergy in Europe

Biedermann

Winther

Till

et al. 2019

Allergy

246

186

View full text Add to dashboard Cite

Birch and other related trees of the families Betulaceae and Fagaceae (alder, hazel, oak, hornbeam, chestnut, and beech) constitute the birch homologous group. This grouping is primarily based on the extensive IgE cross-reactivity of allergen homologs to the major birch allergen Bet v 1. Birch pollen is the most dominant tree pollen in Northern and Central Europe and is a major cause of allergic rhinitis and, possibly, asthma symptoms. Over the last few decades, levels of birch pollen have risen and the period of exposure has increased due to climate changes. Subsequently, the prevalence of birch pollen sensitization has also increased. The cross-reactivity and sequential pollen seasons within the birch homologous group create a prolonged symptomatic allergy period beyond birch pollen alone. Furthermore, many plant food allergens contain homologs to Bet v 1, meaning that the majority of patients with birch pollen allergy suffer from secondary pollen food syndrome (PFS). As a result, the negative impact on health-related quality of life (HRQoL) in patients allergic to birch pollen is significant. The purpose of this manuscript was to narratively review topics of interest such as taxonomy, cross-reactivity, prevalence, clinical relevance, PFS, and HRQoL with regard to birch pollen allergy from a European perspective.

show abstract

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma

Cited by 34 publications

References 33 publications

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma

Insights Into Mucosal Innate Immune Responses in House Dust Mite-Mediated Allergic Asthma

Birch pollen allergy in Europe

Contact Info

Product

Resources

About